Beyond the first posttransplant year, 3% of kidney transplants fail annually. In a prospective, multicenter cohort study, we tested the relative impact of early versus late events on risk of long-term death-censored graft failure (DCGF). In grafts surviving at least 90 days, early events (acute rejection [AR] and delayed graft function [DGF] before day 90) were recorded; serum creatinine (Cr) at day 90 was defined as baseline.
these is that adverse events early in the course of kidney transplantation initiate an inalterable sequence of worsening fibrosis and atrophy over time, resulting in progressive allograft failure. 5, 6 Presumption that this process is inevitable and inexorable is the foundation of diagnoses such as "chronic rejection" and "chronic allograft nephropathy (CAN)."
Delayed graft function (DGF) and acute rejection (AR) are thought to be foremost among consequential early events, and kidneys continuing to function after DGF or early AR are presumed to be at greater risk of late graft failure. [7] [8] [9] The basic observation that AR was associated with decreased long-term graft survival provided the underpinning for using AR (interpreted as a proximate marker for risk of subsequent graft failure) as an endpoint in large clinical trials.
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Emerging data now challenge such an interpretation. In several studies, AR has not correlated with allograft failure, especially when renal function returned to normal after a rejection episode. 11, 12 With standardized histology, supported by molecular analyses, AR is no longer viewed as a monolithic event, but rather the clinical manifestation of several pathophysiologic processes. 13, 14 Indeed, it is now possible to contend that T cell-mediated rejection (if appropriately treated) has no impact on subsequent risk of graft failure. 15 Our understanding of DGF is likewise evolving, with suggestion that the risk associated with DGF may be confined entirely to the early posttransplant period:
Those who recover appear not to be at greater risk of late allograft failure. [16] [17] [18] Notwithstanding these observations, the concept of early injury leading inexorably to graft failure remains widely accepted.
The DeKAF (Long-term Deterioration of Kidney Allograft Function) study was initiated in 2005 as a National Institutes of Health-funded multicenter observational investigation of late allograft failure. 19 DeKAF consists of 2 distinct cohorts of kidney transplant recipients enrolled at 7 transplant centers in the United States and Canada:
(1) all consecutive patients transplanted between 2005 and 2011 (Prospective Cohort) and (2) previously transplanted patients with new-onset graft dysfunction (Cross-Sectional Cohort). 20 Its underlying hypothesis was that late graft failure is not the unalterable consequence of early injury, but rather represents the real-time impact of definable disease entities that occur over the life of an allograft.
If correct, this hypothesis indicates that proper diagnostic categorization would lead to more effective treatment than has been associated with the nonspecific diagnoses of chronic rejection or CAN. Published data from the cross-sectional cohort are supportive. 20, 21 This article is the initial publication of findings from the prospective cohort, a unique aspect of which is collection of data surrounding an index biopsy (IBx:
the first biopsy-for-cause after 90 days posttransplant, triggered by an unexplained rise in serum creatinine [Cr] or new-onset proteinuria, in a patient whose graft survived at least 90 days). These data enable us to examine the impact of risk factors for death-censored graft failure (DCGF) that occur before and after that time point.
| MATERIALS AND METHODS
A detailed description of the DeKAF study can be found at www. Graft survival estimates were obtained using Kaplan-Meier method with the log-log transform used to provide CIs. The c-index-the ability of various Cox proportional hazards models to predict DCGF-was measured using a generalization of concordance and discordance in logistic regression, for models containing the presence of early events or IBx as predictors. C-indices and 95% CIs used Kremers' method and code to account for ties in time and prediction.
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| RESULTS
Of 3774 patients enrolled and followed in the study, 3678 (97.4%) had grafts that survived at least 90 days with a baseline serum Cr value established and additional follow-up beyond Day 90 ( Figure 1 ). and more likely African American (22% versus 16%).
Univariable and multivariable analyses of risk factors for undergoing IBx are shown in Table 2 . By multivariable analysis, significant risk factors associated with requiring an IBx were younger recipient age (HR = 1.18 for every 10-year decrease), older donor age (HR = 1.10
per 10-year increase), CMV status (HR=1.34 donor+/recipient−), and delayed graft function (HR = 1.43).
The mean interval from IBx to graft failure was 16.9 ± 17.4 months (median 10.2 months). Diagnoses related to alloimmune injury at IBx were common (Table 3 ) Univariable and multivariable analyses of risk factors associated with DCGF are shown in Table 4 . By multivariable analysis, risk factors associated with DCGF included younger recipient age (HR = 1.34 for every 10-year decrease), older donor age (HR = 1.20 per 10-year increase), previous kidney transplant (HR = 1.44), AR before day 90 (HR = 1.77), and elevated serum Cr at day 90 (HR = 2.56). However, regardless of early events, experiencing a new episode of renal dysfunction or new-onset proteinuria requiring IBx after day 90 was significantly associated with DCGF (HR = 13.8,
To address concern that IBx reflected a late consequence of early events, we examined whether IBx was associated with additional risk in those with or without early events. Though the rate of IBx among those with early events was slightly higher than in those without early events ( Figure 1 , 208/782, 27% vs 574/2896, 20%), a large majority (76%) of those requiring IBx had no early events. To examine the relative importance of early and late events, we calculated the c-index using a generalization of concordance and dis- Our findings support the recent contention that a kidney transplant, once engrafted, is a relatively stable physiologic entity until something new happens to change the equilibrium. 26 In our cohort of almost 4000 patients, regardless of early events, DCGF was rare without new onset of late dysfunction or proteinuria. Previously published data from our uncontrolled cross-sectional cohort indicated that in the absence of defined alloimmune insult (at mean of 7.6 ± 6 years posttransplant), patients subsequently did well. 19, 21 It is remarkable that findings at IBx in the prospective cohort (Table 3, In addition, these data, derived from a large cohort at multiple centers, confirm the relative inaccuracy of trying to predict late outcomes based on early events and demographics. As shown in Diagnoses grouped under the category of "Other diagnosis" were "suspicious for acute ischemic injury" and "mild tubular dilatation is suggestive of obstruction."
| DISCUSSION
protocol biopsy at 180 days were randomized to standard immunosuppression or discontinuation of tacrolimus. 27 Those randomized to discontinue tacrolimus subsequently experienced significantly more AR, along with new onset of donor-specific antibody, and the study was stopped by its data monitoring committee. Other experience with late posttransplant CNI minimization has also been associated with a If a patient was missing a value of any variable they were excluded from the multivariable analysis (N = 38, mostly for missing donor age [N = 29] or missing donor race [N = 6]). PRA positive categories were not included in the final multivariable model because this information was missing for 221 additional patients.
b P values for overall race, days on dialysis, and induction are given in the first row for each variable.
T A B L E 4 Univariable and multivariable analyses of risk factors for death-censored graft failure (all models were stratified by clinical center) a increased AR rates. [28] [29] [30] [31] In a similar vein, the recently published 7-year outcomes data with belatacept indicate dissociation of beneficial late outcomes from adverse early events. 32 In each of these studies, graft dysfunction and failure late posttransplant reflected late events, regardless of early course. Whether one defines "late" as 90, 180, or even 365 days, our data indicate that trials to evaluate the impact of various potential interventions on long-term graft survival will require longer-term follow-up (as with belatacept), but may be amenable to "late" enrollment and randomization with study populations enriched by later events.
The principal weakness of our study is its attempt to link graft failure with findings obtained at an initial biopsy for dysfunction that yielded a myriad of diagnoses without uniform therapeutic approaches. Likewise, we cannot precisely define onset of processes that injure allografts, nor completely segregate early and later events. These data indicate that monitoring and timely diagnosis applied throughout the posttransplant course may be prerequisite to significantly improving long-term graft survival. Indeed, clinical practice may already be changing, with increasing emphasis on the importance of more intense long-term monitoring in well-functioning grafts, surveillance biopsies, and particular attention to the impact of antibodymediated injury and nonadherence. 4, 31 Critical to these efforts will be improved noninvasive monitoring tools to enable recognition of new graft injury before it is clinically evident. 35, 36 Though, given relative inefficacy of current therapeutic interventions, some might question the benefit of more intense long-term monitoring, we would counter that new therapies can emerge only with timely, proper diagnosis.
To summarize, in our report of over 3600 subjects followed at 7 centers from the time of transplantation, early events were only loosely predictive of late kidney graft dysfunction and failure. In contrast, new onset of allograft dysfunction after 90 days posttransplant was followed by a marked increase in risk for DCGF. In light of these data, it is difficult to view late graft failure as the inexorable consequence of early injury, nor representative of a single diagnostic entity.
Development of effective, cause-specific interventions to preserve kidney transplant function and improve long-term graft survival is dependent on appropriate monitoring, diagnosis, and therapy over the life of the allograft.
